Correlation of Fc Gamma RIIIA Receptor Expression and Response to Rituximab and Other Monoclonal Antibodies in Patients With Waldenstrom's Macroglobulinemia
- A medical data collection survey sheet will be filled out by the patient or doctor with
medical information pertaining to how the patient responded to rituximab and other
monoclonal antibodies for use in this study.
- Blood work will be performed to analyze the blood by molecular technology to find the
kind of Fc gamna RIIIa receptor the patient possess and correlate these findings with
the outcome of treatment with rituximab or other monoclonal antibodies.
Interventional
N/A
Steven Treon, MD, MA, PhD
Principal Investigator
Dana-Farber Cancer Institute
United States: Institutional Review Board
02-075
NCT00142155
January 2002
March 2007
Name | Location |
---|---|
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |